Hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and the short treatment time window comprise major challenges for thrombolytic therapy. Improving tissue plasminogen activator therapy has become one of the highest priorities in the stroke field. Recent efforts have been aimed at identifying new strategies that might enhance the thrombolytic efficacy of tissue plasminogen activ...

the aim of the present research was to study the effects of regular training and exhaustive exercise on t-pa/pai-1 complex in the blood of forty eight rats. they were divided randomly into control and experimental groups and the subgroups included the primary acute, secondary acute and 8-wk regularly trained (each group 8 rats). endurance training programs (five days a week, speed 15-22 m/min f...

BACKGROUND The expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and thus appears to be under epigenetic control. OBJECTIVES The study aimed to test if in vivo pharmacological intervention by valproic acid treatment would lead to increase in tissue plasminogen activator release capacity. METHODS In an anaesthetized pig model, a controlle...

Malignant changes are often accompanied by alterations in activity and composition of the plasminogen activators (PA). To study the relationship between PA expression and the development of colorectal cancer, we determined urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) activity in normal mucosa (n = 80), adenomatous polyps (n = 76), and adenocarcinomas ...

Fibronectin immobilized onto polystyrene surface was found to bind plasminogen and tissue-type plasminogen activator (t-PA) but only slightly the urokinase type as determined using mono- and polyclonal antibodies against the activators. Of the defined fibronectin fragments tested, the Mr 120,000-140,000 fragment was found to bind both plasminogen and t-PA. Proteolytically modified plasminogen (...

Human rTNF/Cachectin was shown to stimulate gene transcription of plasminogen activator inhibitor (PA1)-1 and PAI-2, and simultaneously suppress constitutive gene expression of tissue-type plasminogen activator (t-PA) in human fibrosarcoma cells. We propose that a TNF-mediated reprogramming of gene transcription induces, in appropriate target cells, an anti-fibrinolytic state, which may coopera...

In eighty-three patients with confirmed deep vein thrombosis, the fibrinolytic system was studied before and after a 1 0-minute venous occlusion. Blood was collected at least 3 months after the last acute episode. and PAl-i antigen and activity. as well as tissue-type plasminogen activator (t-PA) antigen. urokinase-type plasminogen activator (uPA) antigen. and fibrinolytic activity were measure...

BACKGROUND AND PURPOSE Thrombolytic agents hold theoretical promise as therapy for cerebral infarction. This study was designed to evaluate the safety of tissue plasminogen activator, to accomplish urgent patient treatment, and to estimate potential efficacy of tissue plasminogen activator. METHODS Following neurological evaluation and computed tomography of the brain, patients with acute isc...